‘One Small Step Closer to an AD Cure’: What Eight-week Maintenance Dosing With Lebrikizumab Means for Eczema Patients and Providers
Eight-week maintenance dosing with lebrikizumab (Ebglyss, Eli Lilly and Company) is a viable strategy for atopic dermatitis (AD) patients, according to results from a 32-week extension trial presented at the 2025 Fall Clinical Dermatology Conference in Las Vegas, NV.